Comparing the Inflammation, Maldigestion and Symptoms Due to Commercial Milk and A2 Milk

Inclusion Criteria:

• • Ability/desire to provide informed consent
• Aged 18 to 65 years of age inclusive at screening
• Current or recent history of intolerance to or avoidance of dairy of at least onemonth duration (by self-report and self-reported symptoms).
• Agrees to refrain from all other treatments and products used for dairyintolerance (e.g., Lactaid® Dietary Supplements) during study involvement
• Willing to return for all study visits and complete all study related procedures
• Able to understand and provide written informed consent in English

Exclusion Criteria:

• • Allergic to milk
• Currently pregnant
• Currently lactating
• Cigarette smoking or other use of tobacco or nicotine containing products within 3 months of screening
• Diagnosed with any of the following disorders known to be associated withabnormal gastrointestinal motility such as; Gastroparesis, amyloidosis,neuromuscular diseases (including Parkinson's disease), collagen vasculardiseases, alcoholism, uremia, malnutrition, or untreated hypothyroidism
• History of surgery that alters the normal function of the gastrointestinal tractincluding, but not limited to: gastrointestinal bypass surgery, bariatricsurgery, gastric banding, vagotomy, fundoplication, pyloroplasty [Note: historyof uncomplicated abdominal surgeries such as removal of an appendix more than 12months prior to screening will not be excluded]
• Past or present : Organ transplant, chronic pancreatitis, pancreaticinsufficiency, symptomatic biliary disease, Celiac disease, chronic constipation,diverticulosis, inflammatory bowel disease (IBD), ulcerative colitis (UC),Crohn's disease (CD), small intestine bacterial overgrowth syndrome (SIBO),gastroparesis, gastro-esophageal reflux disease (GERD), Irritable Bowel Syndrome (IBS) or any other medical condition with symptoms that could confound collectionof adverse events.
• Active ulcers, or history of severe ulcers
• Diabetes mellitus (type 1 and type 2)
• Congestive Heart Failure (CHF)
• Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C
• Height: ___ Weight: ___ BMI: ___ o Weighing <16.5 kg and BMI > 35 kg/m2
• Recent bowel preparation for endoscopic or radiologic investigation within fourweeks of screening (e.g., colonoscopy prep)
• Use of concurrent therapy(ies) or other products (e.g., laxatives, stoolsofteners, Pepto Bismol®, Lactaid® Dietary Supplements) used for symptoms ofdairy intolerance within 7 days of screening
• Chronic antacid and/or PPI use
• Recent use of systemic antibiotics defined as use within 30 days prior toscreening
• Recent high colonic enema, defined as use within 30 days prior to screening
• Any concurrent disease or symptoms which may interfere with the assessment of thecardinal
• symptoms of dairy intolerance (i.e., gas, diarrhea, bloating, cramps, stomachpain)
• History of ethanol (alcohol) and/or drug abuse in the past 12 months
• Currently undergoing chemotherapy
• Use of any investigational drug or participation in any investigational studywithin 30 days prior to screening
• Prior enrollment in this study
• Any other conditions/issues noted by the study staff and/or PrincipalInvestigator that would impact participation and/or protocol compliance